GAO: NIH and FDA Awarded $276M (FY2022–FY2025) to Expand ALS Investigational Drug Access and Research

GAO reports that NIH and FDA awarded about $276 million from FY2022 through FY2025 to implement the ACT for ALS Act, supporting access to investigational ALS drugs and related research. The funding primarily flowed through NIH grants aimed at expanding patient access and accelerating research on ALS and related neurodegenerative diseases.